

**Organizations and institutions in these countries may apply:**

- Afghanistan
- Angola
- Armenia
- Azerbaijan
- Bangladesh
- Benin
- Bhutan
- Bolivia
- Burkina Faso
- Burundi
- Cambodia
- Cameroon
- Central African Republic
- Chad
- Comoros
- Congo
- Dem Rep Congo
- Cote d'Ivoire
- Cuba
- Djibouti
- Eritrea
- Ethiopia
- Gambia
- Georgia
- Ghana
- Guinea
- Guinea-Bissau
- Guyana
- Haiti
- Honduras
- India
- Indonesia
- Kenya
- Kiribati
- Korea, DPR
- Kyrgyz Republic
- Lao PDR
- Lesotho
- Liberia
- Madagascar
- Malawi
- Mali
- Mauritania
- Moldova
- Mongolia
- Mozambique
- Myanmar
- Nepal
- Nicaragua
- Niger
- Nigeria
- Pakistan
- Papua New Guinea
- Rwanda
- São Tomé e Príncipe
- Senegal
- Sierra Leone
- Solomon Islands
- Somalia
- Sri Lanka
- Sudan
- Tajikistan
- Timor Leste
- Togo
- Tanzania
- Uganda
- Ukraine
- Uzbekistan
- Viet Nam
- Yemen
- Zambia
- Zimbabwe

# About the GARDASIL Access Program



Cervical cancer impacts approximately 530,000 women per year, more than 85% of whom live in developing countries (GLOBOCAN 2008). Amidst these statistics, the GARDASIL Access Program is making available at least three million doses of GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant] to qualifying organizations and institutions for use in approved HPV vaccination projects in developing countries.

The GARDASIL Access Program enables organizations and institutions in eligible lowest income countries (see left for list of eligible countries) to gain operational experience designing and implementing HPV vaccination projects, with the goal of supporting development of successful child and adolescent immunization models.

The program accommodates proposals from applicants to design and implement smaller scale HPV vaccination projects, rather than nationwide programs. Endorsement by the Ministry of Health is a critical application prerequisite. The operational experiences and lessons learned by participants in the program are widely disseminated in an effort to contribute to the public knowledge base on HPV vaccine access and child/adolescent immunization models in lowest income countries.

The GARDASIL Access Program is made possible by a pledge from Merck & Co., Inc. [Whitehouse Station, New Jersey, U.S.A.] and is managed by Axios Healthcare Development (AHD), a US non-profit organization, with strategic guidance provided by the independent GARDASIL Access Program Advisory Board comprised of international public health experts. AHD administers the program and reviews and approves all applications.

## Active Projects to Date

To date, 920,000 doses of GARDASIL have shipped to 20 participants in 18 countries, enough to vaccinate more than 306,600 eligible girls:



The following GARDASIL® Access Program participants have received the donated vaccines and have either completed or are actively implementing HPV vaccination projects in their respective countries:

Country	Participating Institution and/or Organization
<b>Bolivia</b>	<b>Project #1:</b> Ministerio de Salud y Deportes (Ministry of Health and Sports)* Centro de Investigacion, Educacion y Servicios (CIES)* International Planned Parenthood Federation (IPPF)* <i>* These organizations have submitted three applications, all of which were recommended by the GARDASIL Access Program Advisory Board and approved by AHD.</i> <b>Project #2:</b> Universidad Mayor de San Andrés (UMSA), Facultad de Medicina
<b>Bhutan</b>	Ministry of Health Australian Cervical Cancer Foundation (ACCF)
<b>Cambodia</b>	Hôpital de l'Amitié Khméro-Soviétique* Association des Médecins Cambodgiens* <i>* These organizations have submitted two applications, both of which were recommended by the GARDASIL Access Program Advisory Board and approved by AHD.</i>
<b>Cameroon</b>	Cameroon Baptist Convention Health Board (CBCHB)
<b>Georgia</b>	National Screening Center Ministry of Health Republican Immunoprophylactic Center
<b>Haiti</b>	Zanmi Lasante (Partners in Health)
<b>Honduras</b>	<b>Project #1:</b> Liga Contra el Cancer Catholic Medical Mission Board (CMMB) <b>Project #2:</b> Hospital Santo Hermano Pedro Betancourt Catholic Medical Mission Board (CMMB)
<b>Ghana</b>	Rural Women's Initiative for Development and Empowerment (RUWIDE) Catholic Medical Mission Board (CMMB) <i>(Vaccination has not yet started)</i>
<b>Guyana</b>	Ministry of Health
<b>Kenya</b>	Moi Teaching and Referral Hospital (MTRH) <i>(Vaccination has not yet started)</i>
<b>Kiribati</b>	Ministry of Health & Medical Services Australian Cervical Cancer Foundation (ACCF)
<b>Lesotho</b>	Ministry of Health and Social Welfare* <i>* The organization has submitted two applications, both of which were recommended by the GARDASIL Access Program Advisory Board and approved by AHD.</i>
<b>Mali</b>	Center for Vaccine Development Mali <i>(Vaccination has not yet started)</i>
<b>Moldova</b>	Ministry of Health Medical Teams International
<b>Nepal</b>	Nepal Network for Cancer Treatment & Research (NNCTR)* Nepal Australian Cervical Cancer Foundation (NACCF)* <i>* These organizations have submitted two applications, both of which were recommended by the GARDASIL Access Program Advisory Board and approved by AHD.</i>
<b>Tanzania</b>	National Institute for Medical Research (NIMR)
<b>Uzbekistan</b>	Ministry of Health Medical Teams International
<b>Uganda</b>	Mildmay Uganda

### Contact Us

For questions about the GARDASIL Access Program or to submit an application, please contact:

GARDASIL Access Program

Axios International

7, Boulevard de la Madeleine

75001 Paris, France

Phone: +33 1 44 860 760 ; Fax: +33 1 44 860 122

Email: [GARDASILaccess@axiosint.com](mailto:GARDASILaccess@axiosint.com)

To learn more about the GARDASIL Access Program, please visit

[www.gardasilaccessprogram.org](http://www.gardasilaccessprogram.org)

